Cipla has launched what it describes as India’s first dedicated sputum inflammometry laboratory, a move aimed at advancing precision diagnosis and treatment for patients with severe respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Pharmaceutical major Cipla has announced the launch of a specialized sputum inflammometry laboratory designed to support the diagnosis and management of complex respiratory conditions. The facility is expected to help clinicians better identify airway inflammation patterns and tailor treatment strategies for patients with severe asthma and other chronic lung diseases.
Sputum inflammometry is a diagnostic technique that analyzes inflammatory cells present in a patient’s sputum sample. The approach enables healthcare professionals to classify different types of airway inflammation, allowing for more personalized treatment decisions rather than relying solely on symptoms or conventional lung function tests.
According to Cipla, the newly launched laboratory will provide clinicians with access to advanced diagnostic capabilities that can improve disease assessment and support evidence-based treatment planning. The company said the facility is intended to address gaps in respiratory disease management, particularly for patients whose symptoms remain uncontrolled despite standard therapies.
Respiratory diseases continue to represent a significant healthcare burden in India, with asthma and COPD affecting millions of people. Medical experts increasingly advocate the use of precision medicine approaches that can identify underlying disease mechanisms and guide targeted interventions.
The laboratory is expected to support pulmonologists and healthcare institutions by providing detailed inflammatory profiling services that may help optimize treatment selection and monitor patient responses over time. Cipla noted that the initiative aligns with broader efforts to strengthen respiratory healthcare infrastructure and improve clinical outcomes.
Industry observers view the launch as an important step in expanding access to advanced respiratory diagnostics in India. As healthcare providers adopt more personalized treatment approaches, diagnostic technologies such as sputum inflammometry are likely to play a larger role in managing chronic respiratory disorders.
The company said the facility reflects its continued focus on respiratory care innovation and the development of specialized healthcare solutions aimed at improving patient management and long-term disease control.
Source: This article is based on a press release issued by Cipla
Cipla Launches First-of-its-kind Sputum Inflammometry Lab | Cipla
